Vaccin mot papillomvirus (humant, typ 6, 11, 16, 18, 31, 33, 45, 52 och 58) Testmiljö
Vaccin mot papillomvirus (humant, typ 6, 11, 16, 18, 31, 33, 45, 52 och 58)
Klass : A
Visa all info
Skriv ut
Kontakta oss
Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
Gardasil 9 (human papillomavirus vaccine, types 6, 11, 16, 18, 31,33, 45, 52, 58). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.
Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
- Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
- Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
- Gardasil 9 (human papillomavirus vaccine, types 6, 11, 16, 18, 31,33, 45, 52, 58). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.
- Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017